InvestSMART

Telix Pharmaceuticals Limited (ASX:TLX)

ALERT: Price-sensitive ASX Announcement for TLX
Current share price for TLX : $17.380 1.93 (12.49%)+
Announcement
Release
14 Apr 2026 5:08PM
Price at Release
$15.450
Full Release
download
Summary
Telix Pharmaceuticals Limited's investor presentation in April 2026 outlines significant growth and advancements in their pipeline and commercial strategy. The company reported strong financial performance with a group revenue of USD 804 million in 2025, a 56% increase year-over-year, and a positive EBITDA of USD 40 million. Telix's precision medicine portfolio is a major growth driver, with new product launches anticipated, including Pixclara® and Illuccix® which have regulatory submissions in process in Europe and China. Their strategic collaboration with Regeneron aims to develop next-generation radiopharmaceutical therapies, offering potential development, commercial milestone payments, and royalties. Telix continues to expand its global footprint with products commercially available in 22 countries and further geographic expansion in China and Japan. The company has outlined strategic priorities for 2026 including increasing R&D investments and meeting regulatory milestones for their therapeutic candidates.
Key Points
  • Telix Pharmaceuticals reported USD 804 million in revenue for 2025, up 56% year-over-year.
  • The company has a strong pipeline with four assets in pivotal or Phase 3 trials.
  • Telix is focused on global expansion, with products available in 22 countries and further expansion planned in China and Japan.
  • Strategic collaboration with Regeneron to develop next-generation radiopharmaceutical therapies.
  • New product launches anticipated for Pixclara® and Illuccix®, with regulatory submissions in Europe and China.
  • R&D investments are set to increase, supported by clinical data outcomes and commercial performance.
  • Precision medicine portfolio is a significant growth driver, with a focus on prostate, kidney, and brain cancer treatments.
  • Group EBITDA was USD 40 million with a positive cash balance of USD 142 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.